Accelerating translational velocity for North American biopharma partners via standardized cellular assays, bio-potency mapping, and IND-enabling analytical methodologies.
A rigorous examination of legislative mandates, alternative test methodologies (NAMs), and strategic CRO outsourcing paradigms for the U.S. biotechnology sector.
The landmark signing of the FDA Modernization Act 2.0 (Public Law 117-328) removed the 1938 federal mandate requiring animal testing for new drug applications. United States pharmaceutical sponsors and biotechs are aggressively deploying cell-based microphysiological systems, 2D/3D human primary cell cultures, and high-throughput organ-on-chip platforms to generate defensible IND-enabling data packages with reduced lead times and ethical overhead.
Botanical active ingredients encounter severe solubility, variability, and complex multi-pathway interaction challenges. Modernized in vitro assay suites enable early-stage screening of natural extract fractionations, isolating molecular mechanisms such as AMPK activation, NF-κB inhibition, and nuclear receptor regulation long before animal studies or clinical phase entries.
Deploying end-to-end preclinical assays domestically within the United States poses significant budgetary hurdles for early-stage and mid-market venture-backed sponsors. MedGence pairs Western regulatory methodologies (GLP, OECD, US Pharmacopeia) with offshore capacity advantages, ensuring cost-efficient data sets without sacrificing evidentiary rigor.
Delivering high-fidelity data packages designed specifically for submission to the U.S. Food and Drug Administration (CDER/CFSAN) and the Environmental Protection Agency (EPA).
Comprehensive MTT, MTS, CCK-8, LDH release, and ATP luminescence assays designed according to ISO 10993-5 and OECD guidance. We test cross-species cell panels to establish clear IC50 concentrations and therapeutic indices for bioactive compounds, botanical matrices, and synthetic formulations.
Caco-2 and MDCK monolayer systems to evaluate bidirectional gut absorption, P-glycoprotein (P-gp) substrate interactions, and compound transport behavior. Crucial for U.S. FDA Biopharmaceutics Classification System (BCS) categorization and dietary supplement bioavailability profiling.
OECD 471 (Bacterial Reverse Mutation / Ames Test), OECD 473 (In Vitro Mammalian Chromosomal Aberration), and OECD 487 (In Vitro Micronucleus Assay) providing complete, non-animal genotoxic risk clearance for U.S. GRAS (Generally Recognized as Safe) and NDI (New Dietary Ingredient) notifications.
Continuous investment in cutting-edge Next-Generation Risk Assessment (NGRA) frameworks and microphysiological technology.
Integration of high-throughput automated imaging to profile phenotypic cell responses across 100+ biomarker channels concurrently.
Human liver spheroids, 3D reconstructed human epidermis (RhE), and intestinal organoids to replicate real organ physiology.
Dynamic fluid shear stress integration with microvascular channels for high-relevance pharmacokinetic modeling.
Computational biology pairing in vitro cell-response RNA sequencing with machine learning to predict in vivo toxicological end-points.
Our study directors are ready to discuss your target endpoints, customized cell lines, and regulatory documentation requirements.
Send Inquiry NowCritical operational, regulatory, and intellectual property answers for U.S. procurement managers and R&D stakeholders.
Review the full scope of our verified research lines, tailored to advance global botanical drug products from crude extract characterization to commercial distribution.
